HKUMed on COVID-19
Combination of mRNA and Inactivated COVID-19 Vaccines, an Open-Label Randomised Controlled Trial | 接種mRNA和滅活的 COVID -19疫苗的混合組合,一項開放標籤的隨機對照試驗


Combination of mRNA (Comiranty) and inactivated (CoronaVac) COVID-19 vaccination might improve the vaccine immunogenicity and safety when compare to vaccination with two doses of the same type of vaccine.

This study by HKU Department of Medicine targets to recruit 150 adult subjects 18 years or above and randomise to receive a single dose of of Comirnaty followed by a single dose of CoronaVac, or two doses of Comirnaty or two doses of CoronaVac. Subjects will be follow-up and assessed for a total of 1 year for vaccine immunogenicity and safety.

與接種兩劑同一類型同一劑量的疫苗相比,mRNA(復必泰)和滅活(克爾來福)2019冠狀病毒病疫苗的聯合使用或可提高疫苗的免疫完成和安全性。

這項港大醫學院內科學系的研究,目的是招募150名18歲或以上的成年人士,並隨機接受單劑量的復必泰疫苗,然後接受單劑量的克爾來福疫苗,與接受兩劑復必泰疫苖或兩劑克爾來福疫苗作比較。我們對受試者進行為期一年的疫苗免疫性和安全性跟進。

Enquiries | 聯絡研究團隊

If you have any further question about this study, please contact study nurse Miss Deborah Ho at HKU Department of Medicine:

如果你對此研究有任何疑問,請聯絡港大醫學院內科學系研究護士何姑娘:

+852 6067 1500